Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines

Maurício Fregonesi Barbosa1,2*, Daniéliso Renato Fusco3, Rafael Dezen Gaiolla4, Konrad Werys5, Suzana Erico Tanni6, Rômulo Araújo Fernandes7, Sergio Marrone Ribeiro2 and Gilberto Szarf1,8

Abstract

Background: The use of anthracycline-based chemotherapy is associated with the development of heart failure, even years after the end of treatment. Early detection of cardiac dysfunction could identify a high-risk subset of survivors who would eventually benefit from early intervention. Cardiac magnetic resonance feature-tracking (CMR-FT) analysis offers a practical and rapid method to calculate systolic and diastolic strains from routinely acquired cine images. While early changes in systolic function have been described, less data are available about late effects of chemotherapy in diastolic parameters by CMR-FT. The main goal of this study was to determine whether left ventricular (LV) early diastolic strain rates (GDSR-E) by CMR-FT are impaired in long-term adult survivors of non-Hodgkin lymphoma (NHL). Our secondary objective was to analyze associations between GDSR-E with cumulative anthracycline dose, systolic function parameters and myocardial tissue characteristics.

Methods: This is a single center cross-sectional observational study of asymptomatic patients in remission of NHL who previously received anthracycline therapy. All participants underwent their CMR examination on a 3.0-T scanner, including cines, T2 mapping, T1 mapping and late gadolinium enhancement imaging. Derived myocardial extracellular volume fraction was obtained from pre- and post-contrast T1 maps. CMR-FT analysis was performed using Trufi Strain software. The data obtained were compared between anthracycline group and volunteers without cardiovascular disease or neoplasia.

Results: A total of 18 adult survivors of NHL, 14 (77.8%) males, at mean age of 57.6 (± 14.7) years-old, were studied 88.2 (± 52.1) months after exposure to anthracycline therapy (median 400 mg/m²). Compared with controls, anthracycline group showed impaired LV global early diastolic circumferential strain rate (GCSR-E) [53.5%/s ± 19.3 vs 72.2%/s ± 26.7, \( p = 0.022 \)], early diastolic longitudinal strain rate (GLSR-E) [40.4%/s ± 13.0 vs 55.9%/s ± 17.8, \( p = 0.006 \)] and early diastolic radial strain rate (GRSR-E) [− 114.4%/s ± 37.1 vs − 170.5%/s ± 48.0, \( p < 0.001 \)]. Impaired LV...
Background
The use of anthracycline chemotherapy is associated with the development of heart failure (HF) among survivors of non-Hodgkin lymphoma (NHL), even years after the end of treatment [1]. Detecting cardiac dysfunction could identify a subgroup of asymptomatic patients at high risk for HF who would eventually benefit from early intervention [2–4]. The most common method of monitoring cardiac function during and after cancer treatment is the measurement of left ventricular (LV) ejection fraction (EF) by 2-dimensional transthoracic echocardiography (TTE) [5, 6], however, EF is not a perfect parameter for the diagnosis of cardiotoxicity, as it does not demonstrate early subtle changes and, when reduced, reflects a serious injury to the cardiomyocyte, followed by a poor outcome [7–9]. More recently, myocardial strain imaging has been shown to be more sensitive than LVEF in the characterization of LV systolic dysfunction following anthracyclines [10, 11]. Cardiac magnetic resonance (CMR) is considered the reference standard for the measurement of ventricular volumes and ejection fraction, mainly related to its advantages of providing unobstructed views of the heart in several planes and high reproducibility [12]. CMR also provides noninvasive assessment of myocardial tissue characteristics, by T1 mapping and derived extracellular volume fraction (ECV), T2 mapping and late gadolinium enhancement (LGE) imaging [13–15]. Cardiac magnetic resonance feature-tracking (CMR-FT) analysis offers a practical and rapid method to calculate strain from routinely acquired steady-state free precession (SSFP) cine images without the need of additional tagged sequences [16]. While changes in systolic function after anthracycline therapy have been described using CMR-FT [17–19], less data are available about late effects of chemotherapy in LV diastolic parameters, although diastolic dysfunction (DD) may precede systolic dysfunction [20–23], providing an earlier marker of cardiotoxicity. Therefore, in the present investigation, we sought to determine whether early diastolic strain rates (GDSR-E) by CMR-FT are impaired in long-term adult survivors of NHL. Our secondary objective was to analyze associations between GDSR-E with cumulative anthracycline dose, systolic function parameters and myocardial tissue characteristics.

Methods
Study design and participants
We conducted a cross-sectional observational study in a tertiary care center, with asymptomatic patients in remission of NHL who previously received anthracycline therapy and had finished their treatment at least 1 year before the enrollment. Patients were excluded if they had active cardiac disease, symptoms consistent with congestive HF, renal insufficiency or usual contraindications for CMR as implantable devices, cerebral aneurysm clips and cochlear implants. Subjects with no evidence of cardiovascular disease or neoplasia, recruited by open invitation, were included in the control group.

This study complied with the Declaration of Helsinki and was approved by the Research Ethics Committee of the Paulista Medical School—UNIFESP (approval number: 897.237) and Botucatu Medical School—UNESP (approval number: 969.316). All participants provided witnessed, written, informed consent.

CMR technique and measurements
All participants underwent their examination on a 3.0-T Magnetom Verio Scanner (Siemens, Erlangen, Germany) with a phased array chest coil, according to study protocol. A cardiac cine steady-state free precession (SSFP) sequence was acquired using retrospective cardiac gating. Typically, 25 phases were acquired in 2-, 3-, and 4-chamber long axis views and a stack of short axis views. Scan parameters: field of view (FOV) 37-cm, repetition time (TR) 43.54 ms, echo time (TE) 1.38 ms, flip angle 50°, slice thickness 6 mm, in-plane image resolution 1.6 × 1.6 mm. Late gadolinium enhancement (LGE) with a single-shot phase-sensitive inversion recovery (PSIR) sequence was acquired in a stack of short axis, 2- and 4-chamber long axis views, 8 to 15 min after intravenous injection of 0.15 mmol/kg of a gadolinium-based contrast agent (gadoterate dimeglumine, Dotarem, Guerbet, France). Scan parameters: FOV 37-cm, TR 600 ms, TE 1.07 ms, flip angle 40°, slice thickness 5–8 mm, in-plane resolution 2.2 × 1.9 mm.

Quantitative T2 mapping was performed using a T2-prepared SSFP sequence with the following imaging parameters: FOV 36-cm, TR 254.32, TE 1.07 ms, flip angle 35°, slice thickness 8 mm, in-plane image resolution

Conclusions: Left ventricular early diastolic strain rates by CMR-FT are impaired late after anthracycline chemotherapy in adult survivors of non-Hodgkin lymphoma.

Keywords: Strain, Feature-tracking, Diastolic dysfunction, Cancer, Chemotherapy
2.5 × 1.9 mm, acquisition in late diastole on every fourth heartbeat; T2 preparations: 0 ms, 25 ms and 55 ms.

Quantitative T1 mapping was performed with a Modified Look-Locker Inversion-Recovery (MOLLI) sequence in mid-cavity short axis, pre-contrast (Native T1) and again at least 15 min after administration of gadolinium, according to previous published consensus [24]. Pre-contrast scan parameters: FOV 36-cm, TR 316.09, TE 1.12 ms, flip angle 35°, slice thickness 8 mm, in-plane image resolution 2.1 × 1.4 mm, acquisition in late diastole on every other heartbeat, minimal inversion time 120 ms; increment 80 ms. The T1 mapping scheme included 5 acquisitions after the first inversion pulse, followed by a 3-heartbeat pause and a second inversion pulse followed by 3 acquisitions [5(3)3]. Post-contrast scan parameters were the same, except by TR 396.09 and T1 mapping scheme that included 4 acquisitions after the first inversion pulse, followed by a 1-heartbeat pause, a second

---

Fig. 1 Representative strain rates profile from CMR-FT of a 64 years-old woman, treated with anthracycline therapy 10 years before CMR exam. This example demonstrates typical strain rates pattern with S (systolic), E (early diastolic), and A (late diastolic) waves in circumferential (a), longitudinal (b) and radial (c) directions.
inversion pulse followed by 3 acquisitions, 1-heartbeat pause and a third inversion pulse followed by 2 acquisitions [4(1)3(1)2].

**CMR analysis**

The biventricular end-diastolic volume (EDV) and end-systolic volume (ESV) were measured by manual segmentation of the short axis cine images, using Argus function software (Siemens, Erlangen, Germany). The endocardial borders were traced at end-diastole and end-systole, including trabeculations and papillary muscles in the blood pool. EDV and ESV were calculated for each ventricle using the method of disc summation. Ventricular stroke volume (SV) was calculated with the difference between the EDV and ESV, and ventricular ejection fraction (%) was (SV/EDV) × 100. LV epicardial borders were draw only at end-diastole to calculate LV mass (M). All volume measurements were indexed for the body surface area (BSA) and expressed in ml/m².

Strain analysis by feature-tracking was performed processing cine images with dedicated software (Trufi Strain, Siemens Healthcare, Medical Imaging Technologies, Princeton, NJ, USA) as previously described [18]. Circumferential and radial strains were analyzed in short axis stack by automatic segmentation of the LV blood pool cavity and myocardium, while longitudinal strains were obtained by manually tracing endocardial and epicardial contours in the first frame of 4-chamber long axis view and then automatically tracked to others frames. Strain values were obtained for each segment and global values defined as the mean of all segmental values. By convention, global longitudinal (GLS) and global circumferential (GCS) systolic strains are expressed as a negative value because it represents shortening of the myocardium relative to the original length, while global radial systolic strain (GRS) is expressed as a positive value because it represents thickening, with impaired GLS, GCS or GRS reflected by a value closer to zero. Otherwise strain rates

---

**Fig. 2** Example of tissue characterization by CMR. Native T1 (a), post-gadolinium T1 with derived ECV (b), T2 mapping (c) and LGE in short axis (d), 2-chamber (e) and 4-chamber (f) views. Red arrow points to focal non-ischemic LGE.
reflects the velocities of deformation between frames. Diastolic strains are expressed as opposite of their counterpart systolic strains (i.e. GLS is expressed as a negative value and global longitudinal early diastolic strain rate (GLSR-E) as a positive value) (Fig. 1).

T1 and T2 maps were automatically generated on the MR scanner with motion corrected images using a novel non-rigid registration algorithm [25–27]. A region of interest (ROI) was then drawn conservatively in the septal myocardium for each map. In T1 maps another ROI was drawn in the blood pool to calculate ECV.

The ECV was calculated as (1-hematocrit) × (ΔR1 myocardium/ΔR1 blood), where Δ R1 = R1 post-contrast – R1 pre-contrast and R1 = 1/T1.

Figure 2 shows an example of tissue characterization by CMR.

Table 1 Comparison of clinical variables between anthracycline and control groups

| Variable                      | Anthracycline (n = 18) | Control (n = 17) | p value |
|-------------------------------|------------------------|-----------------|---------|
| Age (years)                  | 57.6 ± 14.6            | 48.1 ± 12.2     | 0.047   |
| Male (n, %)                   | 14 (77)                | 8 (47)          | 0.601   |
| Height (cm)                  | 168.2 ± 10.2           | 164.1 ± 8.5     | 0.206   |
| Weight (kg)                  | 76.1 ± 15.3            | 69.7 ± 10.0     | 0.160   |
| BMI (kg/m²)                  | 26.8 ± 4.3             | 25.9 ± 2.9      | 0.469   |
| BSA (m²)                     | 1.86 ± 0.22            | 1.76 ± 0.15     | 0.157   |
| Heart rate (bpm)             | 68.7 ± 14.3            | 66.2 ± 14.8     | 0.610   |
| Blood hematocrit (%)         | 44.6 ± 3.7             | 44.2 ± 3.6      | 0.802   |
| SBP (mmHg)                   | 117.2 ± 13.4           | 120.5 ± 7.5     | 0.367   |
| DBP (mmHg)                   | 74.1 ± 8.4             | 76.9 ± 5.8      | 0.255   |
| Smoking (n, %)               | 1 (5)                  | 0 (0)           | 1.000   |
| Hypertension (n, %)          | 5 (27)                 | 4 (23)          | 1.000   |
| Diabetes (n, %)              | 2 (11)                 | 1 (5)           | 1.000   |
| Dyslipidemia (n, %)          | 1 (5)                  | 0 (0)           | 1.000   |
| Framingham risk score (%)    | 7.8 ± 7.0              | 3.8 ± 6.6       | 0.099   |

Data expressed as mean ± standard deviation (SD) or n (%)  
BMI: body mass index, BSA: body surface area, SBP: systolic blood pressure, DBP: diastolic blood pressures

Table 2 Comparison of CMR variables between anthracycline and control groups

| Variable                      | Anthracycline (n = 18) | Control (n = 17) | p value |
|-------------------------------|------------------------|-----------------|---------|
| LVF (%)                      | 62.4 ± 7.5             | 68.0 ± 4.6      | 0.012   |
| LVEDV (ml)                   | 135.8 ± 31.9           | 125.5 ± 38.3    | 0.395   |
| LVEVF (ml)                   | 51.2 ± 16.3            | 40.3 ± 14.9     | 0.048   |
| LVSV (ml)                    | 84.5 ± 21.3            | 85.1 ± 25.4     | 0.932   |
| LVM (g)                      | 118.1 ± 23.6           | 111.6 ± 25.7    | 0.444   |
| LVC (g)                      | 87.9 ± 20.4            | 83.2 ± 21.1     | 0.507   |
| LVM/EDV (g/ml)               | 0.88 ± 0.13            | 0.92 ± 0.14     | 0.487   |
| LVEDV index (ml/m²)          | 73.1 ± 16.1            | 70.2 ± 17.1     | 0.612   |
| LVEVF index (ml/m²)          | 27.5 ± 9.4             | 22.4 ± 7.1      | 0.085   |
| LVSV index (ml/m²)           | 45.6 ± 10.7            | 47.8 ± 11.4     | 0.567   |
| LVM index (g/m²)             | 63.7 ± 10.5            | 62.9 ± 9.9      | 0.823   |
| LVC index (g/m²)             | 47.5 ± 9.1             | 46.9 ± 8.5      | 0.841   |
| RVEF (%)                     | 63.7 ± 7.6             | 67.4 ± 6.8      | 0.143   |
| RVESV (ml)                   | 132.3 ± 40.1           | 127.1 ± 40.5    | 0.701   |
| RVSV (ml)                    | 48.8 ± 19.8            | 42.9 ± 19.7     | 0.382   |
| RVSV (ml/m²)                 | 83.4 ± 24.0            | 84.1 ± 23.3     | 0.933   |
| RVESV index (ml/m²)          | 70.7 ± 19.8            | 70.8 ± 13.8     | 0.994   |
| RVSV index (ml/m²)           | 26.0 ± 10.5            | 23.4 ± 9.9      | 0.450   |
| RVSV (ml/m²)                 | 44.6 ± 11.3            | 47.2 ± 10.2     | 0.479   |
| Native T1 (ms)               | 1262.8 ± 35.5          | 1262.7 ± 31.4   | 0.991   |
| ECV (%)                      | 25.9 ± 0.35            | 25.6 ± 0.25     | 0.779   |
| T2 (ms)                      | 40.9 ± 2.4             | 406.1 ± 1.4     | 0.672   |

Data expressed as mean ± standard deviation (SD) or n (%)  
LVEF: left ventricular ejection fraction, LVEDV: left ventricular end-diastolic volume, LVEVF: left ventricular end-systolic volume, LVSV: left ventricular stroke volume, LVM: left ventricular mass, LVC: left ventricular cardiomyocyte mass [(1-ECV × LVM), RVEF: right ventricular ejection fraction, RVESV: right ventricular end-diastolic volume, RVSV: right ventricular end-systolic volume, RVSV: right ventricular stroke volume, ECV: extracellular volume fraction

Statistical analysis

Kolmogorov–Smirnov test was applied to determine appropriate parametric or nonparametric tests. Quantitative variables were expressed as mean ± standard deviation or median (interquartile range) and compared by Student’s t test or Wilcoxon signed-rank test, whereas qualitative variables were expressed by their frequencies and percentages, and compared by the chi-square test or Fisher’s exact test. Considering a mean difference in diastolic strain rates of 20 ± 20%/s, the alpha error of 0.05 and power of 0.8, for this study we calculated a number of 17 subjects per group. Spearman’s correlations were used to examine the relationship between continuous variables. Univariate linear regression analysis was used to evaluate the influence of clinical and CMR parameters in global circumferential early diastolic strain rate (GCSR-E), GLS-E and global radial early diastolic strain rate (GRSR-E). Univariate variables with a significant correlation were entered into a stepwise multiple regression analysis to determine independent predictors of GCSR-E (model 1), GLS-E (model 2) and GRSR-E (model 3). Data were analyzed using SAS Studio 3.8 and considered significant if p < 0.05.

Results

Clinical characteristics

We selected 20 adult survivors of non-Hodgkin lymphoma from the hospital records. One patient declined in participating and another one had claustrophobia during the CMR examination. So, the anthracycline group comprehended 18 adult survivors of non-Hodgkin lymphoma, treated with the same chemotherapy scheme...
(CHOP-cyclophosphamide, doxorubicin, vincristine, and prednisone), median cumulative anthracycline dose of 400 mg/m² (IQR: 225–400 mg/m²), 14 (77.8%) males, between 32–81 years old (mean 57.6 ± 14.6 yo) that were studied 88.2 (± 52.1) months after exposure to therapy. Two (11.1%) patients received mediastinal radiotherapy at the time of treatment. The control group was composed of 17 subjects from the staff of the hospital or their relatives, without previous history of cardiovascular disease or neoplasia. There were no significant differences on clinical variables including cardiac risk factors between groups, except for age, marginally lower in controls ($p = 0.047$). The main clinical characteristics of the study population are shown in Table 1.

**CMR parameters**

CMR measurements are summarized in Table 2. LV and right ventricular (RV) volumes, EF and LV mass were in the normal range, although LVEF was slight lower in anthracycline group (62.4% ± 7.5 vs 68.0% ± 4.6, $p = 0.012$), with a mild raise in LVESV (51.2 ml ± 16.3 vs 40.3 ml ± 14.9, $p = 0.048$). Focal, non-ischemic LGE was present in at least 01 myocardial segment in 03 patients (16.7%). Native T1, ECV and T2 were similar between anthracycline and control groups (Fig. 3). There were no significant differences in CMR parameters between the two patients who received mediastinal radiation and the other survivors in anthracycline group.

**Strain by CMR-FT**

Strain parameters by CMR-FT are listed in Table 3. Compared with controls, anthracycline group showed impaired LV GCS, GLS, GCSR-E, GLSR-E and GRSR-E (Fig. 4). LV GCSR-E, GLSR-E and GRSR-E correlated with anthracycline dose (Fig. 5), LVEF and systolic strain in the same direction (Fig. 6). Univariate predictors of GCSR-E, GLSR-E and GRSR-E were cumulative anthracycline dose, age, LVEF and systolic strain. Systolic strain was an independent predictor of GCSR-E (Table 4).
GLSR-E (Table 5) and GRSR-E (Table 6) on multivariate analysis, after correcting for age.

Discussion

In the present investigation we demonstrated that GDSR-E measured by CMR-FT are impaired in adult survivors of NHL more than 7 years after anthracycline treatment. To the best of our knowledge, this is the first study focused in analyzing diastolic strain rates by CMR-FT in this setting. Moon et al. [28] found similar results in detecting subclinical myocardial dysfunction in this setting. To the best of our knowledge, this is the first study focused in analyzing diastolic strain rates by CMR-FT in this setting. Moon et al. [28] found similar results in detecting subclinical myocardial dysfunction in this setting.

The pathophysiology of diastolic dysfunction includes impairment of myocardial relaxation and stiffening of the myocardium. Alterations in myocardial collagen properties and an increase in ventricular fibrosis are known to result in reduced LV compliance [40, 41]. Histopathological early stages of anthracycline cardiomyopathy are characterized by myocardial edema, inflammation and vacuolization, whereas in the later stages, diffuse myocardial fibrosis predominates [42–44]. CMR has the unique ability to noninvasively characterize myocardial tissue, providing distinct biosignatures of early inflammatory involvement (raised native T1, ECV and T2) and late interstitial fibrosis and remodeling (raised native T1 and ECV but not T2) [45]. However, we failed to prove associations between GDSR-E and myocardial tissue characteristics. Our study may have been underpowered.


data table

| Variable           | Anthracycline (n=18) | Control (n=17) | p value |
|--------------------|----------------------|---------------|---------|
| LV-GCS (%)         | −14.8 ± 2.8          | −16.7 ± 2.1   | 0.026   |
| LV-GCSR-S (%/s)    | −83.0 ± 18.0         | −88.3 ± 14.0  | 0.333   |
| LV-GCSR-E (%/s)    | 53.5 ± 19.3          | 72.2 ± 26.7   | 0.022   |
| LV-GCSR-A (%/s)    | 50.2 ± 19.2          | 54.4 ± 24.5   | 0.579   |
| LV-GLS (%)         | −12.1 ± 2.9          | −14.1 ± 2.0   | 0.025   |
| LV-GLS-R (%/s)     | −61.2 ± 14.1         | −67.2 ± 11.4  | 0.179   |
| LV-GLS-E (%/s)     | 40.4 ± 13.0          | 55.9 ± 17.8   | 0.000   |
| LV-GLS-R-A (%/s)   | 41.9 ± 14.4          | 47.5 ± 15.7   | 0.282   |
| LV-GRS (%)         | 27.3 ± 7.5           | 30.3 ± 5.2    | 0.184   |
| LV-GRSR-S (%/s)    | 120.2 ± 31.4         | 129.8 ± 22.4  | 0.300   |
| LV-GRSR-A (%/s)    | −114.4 ± 37.1        | −170.5 ± 48.0 | <0.001  |
| LV-GRSR-R (%/s)    | −86.6 ± 51.0         | −80.3 ± 41.3  | 0.692   |
| RV-GLS (%)         | −14.2 ± 3.7          | −15.4 ± 3.6   | 0.326   |
| RV-GLS-R (%/s)     | −70.5 ± 20.6         | −81.7 ± 23.9  | 0.147   |
| RV-GRS-E (%/s)     | 45.1 ± 20.1          | 56.0 ± 15.7   | 0.083   |
| RV-GRSR-A (%/s)    | 59.9 ± 25.6          | 57.1 ± 24.5   | 0.736   |

Data expressed as mean ± standard deviation (SD)

GCS global circumferential strain, GCSR-S global circumferential systolic strain rate, GCSR-E global circumferential early diastolic strain rate, GCSR-A global circumferential late diastolic strain rate, GLS global longitudinal strain, GLSR-E global longitudinal systolic strain rate, GLSR-A global longitudinal early diastolic strain rate, GLSR-R-A global longitudinal late diastolic strain rate, GRS global radial strain, GRSR-S global radial systolic strain rate, GRSR-E global radial early diastolic strain rate, GRSR-A global radial late diastolic strain rate, LV left ventricular, RV right ventricular.
to demonstrate this association as it was not our primary objective, although stiffening of the myocardium by edema or fibrosis could be associated with a more restrictive filling pattern rather than impaired relaxation, suggesting GDSR-E could conceptually be a more sensitive and earlier marker of cardiotoxicity.

We found a significant association between GDSR-E and systolic function parameters (LVEF and systolic strain), and in a multivariate analysis reduced systolic strain was an independent predictor of impaired early diastolic strain rates, even when age was considered as confounder. Similar to us, Stoodley et al. [46] reported altered diastolic strain by TTE and its association with systolic dysfunction 1 week after anthracycline therapy and Boyd et al. [47] showed that anthracycline-related diastolic dysfunction was more common in the subgroup with reduced GLS compared to those without changes in GLS. These findings could be explained because GDSR-E provide similar diagnostic information as LV regional lengthening velocity (E') measured noninvasively by tissue Doppler imaging and reflects relaxation as well as restoring forces [48]. Restoring forces are generated in systole by a complex set of mechanisms, LV myocardial wall stores energy in the form of elastic recoil, and this energy is released when the myocardium relaxes. So, GDSR-E are determined in part by systolic function,
reflecting the tight coupling between systolic and diastolic function [49]. Indeed, in a recent study Ito et al. [50] demonstrated that among heart failure with preserved ejection fraction patients, which anthracycline related cardiotoxicity could represent a subset, CMR-FT GLS was independently associated with invasive measures of LV relaxation.

Fig. 5 Relationship between GDSR-E and anthracycline dose. a A negative correlation was found between the GCSR-E and cumulative anthracycline dose ($r = -0.43, p = 0.009$). b A negative correlation was found between the GLSR-E and cumulative anthracycline dose ($r = -0.45, p = 0.005$). c A positive correlation was found between the GRSR-E and cumulative anthracycline dose ($r = 0.56, p < 0.001$)
Study limitations
This study is limited by the small sample size and cross-sectional design, so further corroboration of these findings in prospective larger-scale multicenter studies is required. Likewise, we cannot say whether the impairment in GDSR-E occurred previously or concomitantly with the reduction in systolic strain. As anthracycline patients were marginally older than controls we cannot exclude some influence of the age in the observed difference of GDSR-E measures between the two groups. Also, longer follow-up is necessary to determine if GDSR-E measured by CMR-FT will predict the development of symptomatic heart failure or will be helpful in guiding therapy. We studied only long-term survivors instead of all patients treated with anthracycline-based chemotherapy in our institution, therefore some bias of selection has to be considered.

Conclusions
In this study we demonstrated that left ventricular GDSR-E by CMR-FT are impaired late after anthracycline chemotherapy in adult survivors of NHL. Impaired GDSR-E were associated with cumulative anthracycline dose and systolic function parameters. There were no correlations between GDSR-E and myocardial tissue characteristics.
Table 4  Determinants of global circumferential early diastolic strain rate

| Independent variables | Univariate variable (GCSR-E) | Multiple analysis (r² 0.44, p < 0.001) |
|-----------------------|-----------------------------|---------------------------------------|
|                       | B Coef 95% CI    | p   | B Coef 95% CI | p  |
| Cumulative dose       | −0.04 (−0.09,−0.01) | 0.029 | −     | −    |
| Time after therapy    | −0.06 (−0.25,0.13)  | 0.503 | −     | −    |
| Age (years)           | −0.75 (−1.30,0.19)  | 0.009 | −0.82 (−1.29,0.35) | 0.001 |
| Gender (female)       | 6.09 (−11.66,23.85) | 0.489 | −     | −    |
| Smoking (Yes)         | −18.38 (−69.86,33.08) | 0.472 | −     | −    |
| Hypertension (no)     | 13.08 (−6.14,32.31)  | 0.175 | −     | −    |
| Diabetes (no)         | −16.32 (−46.65,14.00) | 0.281 | −     | −    |
| Dyslipidemia (no)     | 1.79 (−50.08,53.67)  | 0.944 | −     | −    |
| Prior radiotherapy (no)| 9.31 (−27.78,46.40)  | 0.612 | −     | −    |
| LVEF                  | 1.64 (0.50,2.79)     | 0.006 | −     | −    |
| LVMi                  | 0.18 (−0.67,1.05)    | 0.663 | −     | −    |
| LGE (no)              | 8.99 (−21.71,39.70)  | 0.555 | −     | −    |
| Native T1             | −0.10 (−0.36,0.15)   | 0.424 | −     | −    |
| ECV                   | −1.07 (−3.89,1.75)   | 0.466 | −     | −    |
| T2                    | 1.56 (−2.87,5.99)    | 0.478 | −     | −    |
| GCS                   | −4.37 (−7.28,−1.47)  | 0.004 | −4.74 (−7.25,−2.23) | <0.001 |

**Abbreviations**

- BSA: Body surface area; CMR: Cardiac magnetic resonance; CMR-FT: Cardiac magnetic resonance feature-tracking; DD: Diastolic dysfunction; ECV: Extracellular volume fraction; EDV: End-diastolic volume; ESV: End-systolic volume; FOV: Field of view; GCS: Global peak systolic circumferential strain; GCSR-A: Global circumferential late diastolic strain rate; LVEF: Left ventricular ejection fraction; LVMi: Left ventricular mass index; LGE: Late gadolinium enhancement; T1: T1 relaxation time; T2: T2 relaxation time; GLS: Global longitudinal strain

Table 5  Determinants of global longitudinal early diastolic strain rate

| Independent variables | Univariate variable (GLSR-E) | Multiple Analysis (r² 0.44, p < 0.001) |
|-----------------------|-----------------------------|---------------------------------------|
|                       | B Coef 95% CI    | p   | B Coef 95% CI | p  |
| Cumulative dose       | −0.03 (−0.06,−0.01) | 0.009 | −     | −    |
| Time after therapy    | 0.07 (0.05,0.19)   | 0.245 | −     | −    |
| Age (years)           | −0.28 (−0.70,0.13)  | 0.173 | −0.43 (−0.76,0.10) | 0.012 |
| Gender (female)       | 7.45 (−4.70,19.60)  | 0.212 | −     | −    |
| Smoking (Yes)         | −0.56 (−36.63,35.51) | 0.975 | −     | −    |
| Hypertension (no)     | 9.12 (−4.24,22.48)  | 0.174 | −     | −    |
| Diabetes (no)         | −13.74 (−34.65,7.16) | 0.190 | −     | −    |
| Dyslipidemia (no)     | 12.87 (−22.91,48.65) | 0.469 | −     | −    |
| Prior radiotherapy (no)| −2.80 (−28.67,23.07) | 0.827 | −     | −    |
| LVEF                  | 1.25 (0.47,2.02)    | 0.002 | −     | −    |
| LVMi                  | −0.25 (−0.85,0.33)  | 0.384 | −     | −    |
| LGE (no)              | −2.80 (−28.67,23.07) | 0.827 | −     | −    |
| Native T1             | −0.05 (−0.23,0.13)  | 0.559 | −     | −    |
| ECV                   | 0.33 (−1.64,2.31)   | 0.730 | −     | −    |
| T2                    | −0.27 (−3.41,2.87)  | 0.861 | −     | −    |
| GLS                   | −3.65 (−5.53,−1.77) | <0.001 | −4.09 (−5.86,−2.33) | <0.001 |

**Abbreviations**

- Exr: Extracellular volume fraction; EDV: End-diastolic volume; EF: Ejection fraction; LVEF: Left ventricular ejection fraction; LVMi: Left ventricular mass index; LGE: Late gadolinium enhancement; ECV: Extracellular volume fraction; GCS: Global circumferential strain; GLS: Global longitudinal strain;
Table 6  Determinants of global radial early diastolic strain rate

| Independent variables | Dependent variable (GRSR-E) | Univariate Analysis | Multiple analysis (r² 0.64, p < 0.001) |
|-----------------------|------------------------------|---------------------|----------------------------------------|
|                       | B Coef | 95% CI       | p            | B Coef | 95% CI       | p            |
| Cumulative dose       | 0.14   | (0.06;0.22)  | < 0.001     |            | –            | –            |
| Time after therapy    | 0.29   | (–0.04;0.64) | 0.082       |            | –            | –            |
| Age (years)           | 1.26   | (0.07;2.45)  | 0.037       | 1.92     | (0.99;2.85)  | < 0.001     |
| Gender (female)       | −21.70 | (−57.62;14.21) | 0.227 |            | –            | –            |
| Smoking (Yes)         | 24.36  | (−81.83;130.55) | 0.643 |            | –            | –            |
| Hypertension (no)     | −21.13 | (−61.05;18.78) | 0.289 |            | –            | –            |
| Diabetes (no)         | 0.85   | (−62.55;64.26) | 0.978 |            | –            | –            |
| Dyslipidemia (no)     | 32.56  | (−73.35;138.48) | 0.535 |            | –            | –            |
| Prior radiotherapy (no) | −36.91 | (−112.26;38.43) | 0.326 |            | –            | –            |
| LVEF                  | 1.64   | (0.50;2.79)  | 0.006       |            | –            | –            |
| LVMI                  | −0.40  | (−2.18;1.36) | 0.642       |            | –            | –            |
| LGE (no)              | −49.56 | (−110.49;11.36) | 0.107 |            | –            | –            |
| Native T1             | 0.02   | (−0.51;0.57) | 0.912       |            | –            | –            |
| ECV                   | 2.07   | (−3.73;7.88) | 0.471       |            | –            | –            |
| T2                    | −3.87  | (−12.91;5.16) | 0.389 |            | –            | –            |
| GRS                   | −3.94  | (−6.28;−1.61) | 0.001       | 5.05     | (−7.03;−3.07) | < 0.001     |

LVEF left ventricular ejection fraction, LVMI left ventricular mass index, LGE late gadolinium enhancement, ECV extracellular volume fraction, GRS global radial strain

GCSR-E: Global circumferential early diastolic strain rate; GCSR-S: Global circumferential systolic strain rate; GDSR-E: Early diastolic strain rates; GLS: Global peak systolic longitudinal strain; GLSR-A: Global longitudinal late diastolic strain rate; GLSR-E: Global longitudinal early diastolic strain rate; GLSR-S: Global longitudinal systolic strain rate; GRS: Global peak systolic radial strain; GSR-A: Global radial late diastolic strain rate; GSR-E: Global radial early diastolic strain rate; GSR-S: Global radial systolic strain rate; HF: Heart failure; LGE: Late gadolinium enhancement; LV: Left ventricle/ventricular; MOLLI: Modified Look-Locker inversion-recovery; NHL: Non-Hodgkin lymphoma; PSIR: Phase-sensitive inversion recovery; RCR: Region of interest; RV: Right ventricle/ventricular; SD: Standard deviation; SSFP: Steady-state free precession; SV: Stroke volume; TE: Echo time; TR: Repetition time; TTE: 2-Dimensional transthoracic echocardiography.

Acknowledgements
We would like to thank Mr. Ralph Strecker and Mr. Paulo Eduardo Mazo from Siemens Healthcare to provide access to work-in-progress # 448B (VB17A) quantitative cardiac parameter mapping (T1|T2|T2*) and MR Cardiac TruFi strain software. We also thank all patients and volunteers who participated in this study.

Authors’ contributions
MFB: Conception and design, analysis and interpretation of data, drafting of the manuscript and final approval of the manuscript. DRF: Conception and design, analysis and interpretation of data, revising it critically for important intellectual content and final approval of the manuscript. RDG: Conception and design, drafting of the manuscript and final approval of the manuscript. MFB: Conception and design, analysis and interpretation of data, revising it critically for important intellectual content and final approval of the manuscript. All authors read and approved the final manuscript.

Funding
This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES)—Finance Code 001.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study protocol was approved by the Research Ethics Committee of the Paulista Medical School—UNIFESP (approval number: 897.237) and Botucatu Medical School—UNESP (approval number: 969.316). Written informed consent was obtained from each participant.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of Diagnostic Imaging, Universidade Federal de São Paulo (UNIFESP), Rua Napoleão de Barros 800, Vila Clementino, São Paulo 04024-002, Brazil. 2 Department of Tropical Diseases and Diagnostic Imaging, Universidade Estadual Paulista (UNESP), Botucatu, Brazil. 3 Cardiology Division, Internal Medicine Department, Universidade Estadual Paulista (UNESP), Botucatu, Brazil. 4 Hematology Division, Internal Medicine Department, Universidade Estadual Paulista (UNESP), Botucatu, Brazil. 5 University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR), University of Oxford, Oxford, UK. 6 Pneumology Division, Internal Medicine Department, Universidade Estadual Paulista (UNESP), Botucatu, Brazil. 7 Department of Physical Education, Universidade Estadual Paulista (UNESP), Presidente Prudente, Brazil. 8 Hospital Israelita Albert Einstein, São Paulo, Brazil.
References

1. Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006;107(7):2912–9.

2. Herquet D, Le QH, Mouillet I, Pauli E, Salles G, Espinouse D, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol. 2004;22(10):1864–71.

3. Nagy AC, Cserep Z, Tolday E, Nagykalnai T, Forster T. Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study. Pathol Oncol Res. 2008;14(1):69–77.

4. Sawaya MS, Leinhan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2006;24(9):1201–3.

5. Cardinale D, Colombo L, Basetto G, Meregalli G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2005;45(6):607–16.

6. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Gallerani M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.

7. Ewer MS, Leinhan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2006;24(9):1201–3.

8. Cardinale D, Colombo L, Basetto G, Meregalli G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2005;45(6):607–16.

9. Lopez-Fernandez T, Martin Garcia A, Santaballa Beltran A, Montero Luis A, Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.

10. Driscoll AJ, Febos IA, Leinhan DJ. Cardiac magnetic resonance Imaging in an adult human population: serial applications of T1 and T2 mapping. J Thorac Imaging. 2014;29(3):147–54.

11. Hofmann R, von Bardeleben S, ten Cate F, Borges AC, Kasprzak J, Firschke M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063–93.

12. Zamarano JL, Lancellotti R, Rodriguez Munoz D, Aboyans V, Asteggiano R, Gallerani M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–801.

13. Ewer MS, Leinhan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol. 2006;24(9):1201–3.

14. Cardinale D, Colombo L, Basetto G, Meregalli G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2005;45(6):607–16.

15. Hofmann R, von Bardeleben S, ten Cate F, Borges AC, Kasprzak J, Firschke M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063–93.

16. Yoneyama K, Venkatesh BA, Bluemke DA, McClelland RL, Lima JAC. Alterations in left ventricular diastolic function with doxorubicin therapy. JACC Cardiovasc Imaging. 2013;6(8):877–85.

17. Lopez-Fernandez T, Martin Garcia A, Santaballa Beltran A, Montero Luis A, Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–8.

18. Driscoll AJ, Febos IA, Leinhan DJ. Cardiac magnetic resonance Imaging in an adult human population: serial applications of T1 and T2 mapping. J Thorac Imaging. 2014;29(3):147–54.

19. Yoneyama K, Venkatesh BA, Bluemke DA, McClelland RL, Lima JAC. Alterations in left ventricular diastolic function with doxorubicin therapy. JACC Cardiovasc Imaging. 2013;6(8):877–85.

20. Selvan-Mangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouanoud C, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr. 2006;7(2):141–6.

21. Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson. 2017;19(1):234.

22. Girl S, Chung YC, Merchant A, Mihai G, Rajagopalan S, Raman SV, et al. T2 quantification for improved detection of myocardial edema. J Cardiovasc Magn Reson. 2009;11:56.

23. Xue H, Shah S, Greisler A, Guetter C, Littmann A, Jolly MP, et al. Motion correction for myocardial T1 mapping using image registration with synthetic image estimation. Magn Reson Med. 2012;67(6):1644–55.

24. Kellman P, Wilson JR, Xue H, Ugander M, Arai AE. Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method. J Cardiovasc Magn Reson. 2012;14:63.

25. Moon TJ, Miyamoto SD, Younoszai AK, Landbeck BF. Left ventricular strain and strain rates are decreased in children with normal fractional shortening after exposure to anthracycline chemotherapy. Cardiol Young. 2014;24(5):854–65.

26. Claus P, Omar AJS, Pedriozetti G, Sengupta PP, Nagel E. Tissue tracking technology for assessing cardiac mechanics. JACC Cardiovasc Imaging. 2015;8(12):1444–60.

27. Wang J, Khoury DS, Thohan Y, Torre-Amione G, Naghuef S. Global diastolic stress rate for the assessment of left ventricular relaxation and filling pressures. Circulation. 2007;115(11):1376–83.

28. Dokhanish H, Sengupta R, Pillai M, Boffet J, Lakkis N. Usefulness of new diastolic strain and strain-rate indexes for the estimation of left ventricular filling pressure. Am J Cardiol. 2008;101(10):1504–9.

29. Serrano JM, Gonzalez I, Del Castillo S, Muniz J, Morales L, Moreno F, et al. Diastolic dysfunction following anthracycline-based chemotheraphy in breast cancer patients: incidence and predictors. Oncologist. 2015;20(8):864–72.

30. Rammeloo LAJ, Postma A, Sobotka-Plohar MA, Bink-Boekels MTE, Berg AD, Veerman AJP, et al. Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group. Med Pediatr Oncol. 2000;35(1):13–9.

31. Cove-Smith L, Woodhouse N, Hargreaves A, Kirk J, Smith S, Price SA, et al. An integrated characterisation of serological, pathological and functional events in doxorubicin-induced cardiotoxicity. Toxicol Sci. 2014;140(1):13–5.

32. Moulin M, Piquereau J, Mateo P, Fortin D, Rucker-Martin C, Gressette M, et al. Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling. Circ Heart Fail. 2015;8(1):98–108.

33. Stoylen A, Stordahl S, Skjelvan GK, Heimdal A, Skjeiepe T. Strain rate imaging in normal and reduced diastolic function: comparison with pulsed Doppler tissue imaging of the mitral annulus. J Am Soc Echocardiogr. 2001;14(4):264–74.
37. Firstenberg MS, Smedira NG, Greenberg NL, Prior DL, McCarthy PM, Garcia MJ, et al. Relationship between early diastolic intraventricular pressure gradients, an index of elastic recoil, and improvements in systolic and diastolic function. Circulation. 2001;104:330–5.
38. Gong Y, Ong G, Breiden-Aslesley C, Dhir V, Deva DP, Chan KK, et al. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study. Int J Cardiovasc Imaging. 2019;35:653–62.
39. Reuevkep EJ, Bulent BF, Nieuwenhuis AA, Meekes MR, de Haan AF, Tol J, et al. Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radio-nuclide angiography (MUGA). J Nucl Cardiol. 2016;23(4):824–32.
40. Gilbert JC, Glantz SA. Determinants of left ventricular filling and of the diastolic pressure-volume relation. Circ Res. 1989;64(5):827–52.
41. Martos R, Baugh J, Ledwidge M, O’Loughlin C, Conlon C, Patle A, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115(7):888–95.
42. Farhad H, Staziaki PV, Addison D, Coelho-Filho OR, Shah RV, Mitchell RN, et al. Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging. Circ Cardiovasc Imaging. 2016;9(12):e003584.
43. Galan-Arriola C, Lobos M, Vilchez-Tschirschke JP, Lopez GJ, de Molina-Iracleta A, Perez-Martinez C, et al. Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol. 2019;73(7):779–91.
44. Neilan TG, Coelho-Filho OR, Shah RV, Feng JH, Pena-Herrera D, Mandry D, et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am J Cardiol. 2013;111(5):717–22.
45. Hailbauer JD, Lindner S, Valbuena-Lopez S, Zainal H, Zho H, D’Angelo T, et al. CMR imaging biosignature of cardiac involvement due to cancer-related treatment by T1 and T2 mapping. Int J Cardiol. 2019;15(275):179–86.
46. Stoodley PW, Richards DA, Boyd A, Hui R, Harnett PR, Meikle SR, et al. Altered left ventricular longitudinal diastolic function correlates with reduced systolic function immediately after anthracycline chemotherapy. Eur Heart J Cardiovasc Imaging. 2013;14(3):228–34.
47. Boyd A, Stoodley P, Richards D, Hui R, Harnett P, Vo K, et al. Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study. PLoS ONE. 2017;12(4):e0175544.
48. Opdahl A, Remme EW, Helle-Valle T, Lyseggen E, Vartdal T, Pettersen E, et al. Determinants of left ventricular early-diastolic lengthening velocity: independent contributions from left ventricular relaxation, restoring forces, and lengthening load. Circulation. 2009;119(19):2578–86.
49. Flachskampf FA, Biering-Sørensen T, Solomon SD, Duvernoy O, Bjerner T, Smiseth OA. Cardiac imaging to evaluate left ventricular diastolic function. JACC Cardiovasc Imaging. 2015;8(9):1071–93.
50. Ito H, Ishida M, Makino W, Goto Y, Ichikawa Y, Kitagawa K, et al. Cardiovascular magnetic resonance feature tracking for characterization of patients with heart failure with preserved ejection fraction: correlation of global longitudinal strain with invasive diastolic functional indices. J Cardiovasc Magn Reson. 2020;22(1):42.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.